SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, is expanding its EVERIC speciality vial portfolio with a new amber-coloured option made from FIOLAX amber pharma glass.
In combination with the hydrophobic inner coating EVERIC lyo, the vial is ideally suited for lyophilised, highly light-sensitive medications, particularly next-generation antibody-drug conjugates (ADCs) used in targeted cancer therapies.
“ADCs are among the most promising innovations in today’s biologics pipeline. We are proud to introduce another high-value solution that protects these sensitive therapies from the very beginning of the process”, says Andreas Reisse, CEO of SCHOTT Pharma.
“This launch marks another important step in our commitment to enabling the safe delivery of complex biologics and to shaping the future of pharmaceutical packaging through innovation.”
EVERIC lyo and amber addresses the growing need for light protection at the primary packaging level, ensuring the integrity of sensitive drugs already during filling.
With its hydrophobic inner surface, it offers a lotus effect for efficient drug manufacturing and use and sets a new benchmark for ADCs that require lyophilisation.
Manufactured with precisely controlled light transmission properties, this vial is the first on the market that meets all regulatory light transmission requirements across major Pharmacopoeias in Europe, the United States, and Japan.
Targeted protection for one of the most promising drug classes in oncology
ADCs are among the most innovative drug classes in modern oncology. By combining targeted antibodies with highly potent cytotoxic agents, they enable precise cancer treatments with reduced side-effects.
At the same time, ADCs rank among the most complex, sensitive, and costly pharmaceuticals on the market.
Some of these therapies are particularly sensitive to light, which can compromise their stability, efficacy and shelf-life.
Ensuring reliable light protection throughout the entire product lifecycle is therefore critical.
Several ADCs currently approved or in clinical development show light sensitivity as early as the filling stage.
Traditional secondary packaging is no longer sufficient to safeguard these drug products. Instead, a specialised primary packaging solution is required that delivers consistent and certified light protection from the outset.
EVERIC lyo and amber: designed for lyophilised ADCs
With EVERIC amber, SCHOTT Pharma extends its proven speciality vial platform to include high-quality FIOLAX amber borosilicate glass.
The vials are manufactured using a precisely controlled hot-forming process. Specialised converting configurations enable tight dimensional tolerances and targeted light transmission adjustment, ensuring the level of protection required for light‑sensitive medications.
For lyophilised ADCs, the hydrophobic inner coating EVERIC lyo offers added value by reducing both product loss and process risk.
It minimises fogging during lyophilisation and improves residual emptying, making it particularly effective for preserving expensive and sensitive drug formulations.
The coating is applied using SCHOTT Pharma’s patented PICVD technology, forming a covalent bond with the glass surface. Unlike siliconised vials, this process eliminates the risk of free silicone contamination in the drug.
Two in-production release criteria, documented in the Certificate of Analysis (CoA), ensure consistent quality and regulatory compliance of EVERIC lyo and amber vials.
“With this innovation, we’re offering pharmaceutical companies a drug containment solution that meets the specific requirements of next-generation ADCs from the filling line all the way to the patient”, says Diana Löber, Global Product Manager at SCHOTT Pharma.
Like all vials in the EVERIC portfolio, EVERIC lyo and amber is modular and customisable and is manufactured exclusively at SCHOTT Pharma’s German site in Müllheim.
